Transition clinic attendance is associated with improved beliefs and attitudes toward medicine in patients with inflammatory bowel disease

Table 2 Disease-specific knowledge and self-reported adherence to prescribed medical therapy n (%)

	Transition	Control	P value
Knowledge1
Diagnosis	44 (78.6)	44 (80.0)	1.00
Prior GI surgery	50 (84.7)	49 (89.1)	0.49
Adherence2
Medication3
5-ASA	8 (57.1)	13 (65.0)	0.73
IM	10 (58.8)	7 (58.3)	1.00
Anti-TNF	5 (83.3)	3 (50.0)	0.55
Combination	13 (76.9)	4 (80.0)	1.00
Any	29 (67.4)	21 (56.8)	0.33
Regular blood work	31 (68.9)	18 (60.0)	0.43

¹Knowledge is defined as concordant physician records and patient responses;

²Adherence is defined as missing less than 30% of prescribed therapy;

³Subgroups in medication row denote patients receiving oral 5-ASA products, IM only, anti-TNF only, combination therapy (IM and anti-TNF) only, or any IBD medication. 5-ASA: 5-aminosalicylic acid; anti-TNF: Anti-tumour necrosis factor agents including infliximab and adalimumab; IM: Immunomodulators including methotrexate, 6-mercaptopurine, and azathioprine.